Exhibit 99.2
Consolidated Financial Statements
December 31, 2021
March 16, 2022
Management’s Responsibility for Financial Reporting
The accompanying consolidated financial statements of IMV Inc. (the “Corporation”) are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. The consolidated financial statements include some amounts and assumptions based on management’s best estimates which have been derived with careful judgment.
In fulfilling its responsibilities, management has developed and maintains a system of internal accounting controls. These controls are designed to ensure that the financial records are reliable for preparation of the consolidated financial statements. The Audit Committee of the Board of Directors reviewed and approved the Corporation’s consolidated financial statements and recommended their approval by the Board of Directors.
| ||||
(signed) |
“Andrew Hall” |
|
(signed) |
“Pierre Labbé” |
Chief Executive Officer |
Chief Financial Officer | |||
|
Approved on behalf of the Board of Directors
| ||||
(signed) |
“Andrew Hall”, Director |
(signed) |
“Kyle Kuvalanka”, Director | |
|
Report of Independent Registered Public Accounting Firm (PCAOB ID: Number
To the Board of Directors and Shareholders of IMV Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of IMV Inc. and its subsidiaries (together, the Company) as of December 31, 2021, December 31, 2020 and January 1, 2020, and the related consolidated statements of equity, loss and comprehensive loss and cash flows for the years ended December 31, 2021 and 2020, including the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, December 31, 2020 and January 1, 2020, and its financial performance and its cash flows for the years ended December 31, 2021 and 2020 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Substantial Doubt About the Company’s Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred significant operating losses and negative cash flows from operations since inception and has an accumulated deficit as of December 31, 2021, and has stated that these events or conditions indicate that a material uncertainty exists that may cast substantial doubt on the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company changed its functional and presentation currency to the United States dollar in 2021.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/
March 16, 2022
We have served as the Company's auditor since 2003.
| |
IMV Inc. | |
Consolidated Statements of Financial Position | |
As at December 31, 2021, December 31, 2020 and January 1, 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
December 31, |
December 31, |
January 1, | |||||
2021 |
2020 |
2020 | |||||
$ |
$ |
$ | |||||
(Recast - note 2) |
(Recast - note 2) | ||||||
Assets | |||||||
| |||||||
Current assets | |||||||
Cash and cash equivalents |
|
|
| ||||
Amounts receivable (note 6) |
|
|
| ||||
Prepaid expenses |
|
|
| ||||
Investment tax credits receivable |
|
|
| ||||
| |||||||
|
|
| |||||
| |||||||
Property and equipment (note 9) |
|
|
| ||||
| |||||||
|
|
| |||||
| |||||||
Liabilities | |||||||
| |||||||
Current liabilities | |||||||
Accounts payable, accrued and other liabilities (note 7) |
|
|
| ||||
Current portion of long-term debt (note 10) |
|
|
| ||||
Current portion of lease obligation (note 8) |
|
|
| ||||
Warrant liabilities (note 11) |
|
|
| ||||
| |||||||
|
|
| |||||
| |||||||
Lease obligation (note 8) |
|
|
| ||||
| |||||||
Long-term debt (note 10) |
|
|
| ||||
| |||||||
|
|
| |||||
| |||||||
Equity |
|
|
| ||||
| |||||||
|
|
| |||||
|
Going concern (note 1) |
The accompanying notes form an integral part of these audited annual consolidated financial statements.
| |
IMV Inc. | |
Consolidated Statements of Equity | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
Accumulated | ||||||||||||||||
other | ||||||||||||||||
Share |
Contributed |
comprehensive | ||||||||||||||
Capital |
Surplus |
Warrants |
Deficit |
income |
Total | |||||||||||
$ |
$ |
$ |
$ |
$ |
$ | |||||||||||
(note 12) |
(note 13) |
(note 14) | ||||||||||||||
Balance, January 1, 2020 (recast – note 2) |
|
|
|
( |
) |
|
| |||||||||
| ||||||||||||||||
Net loss for the period |
– |
– |
– |
( |
) |
– |
( |
) | ||||||||
Other comprehensive income |
– |
– |
– |
– |
|
| ||||||||||
Total comprehensive loss for the period |
– |
– |
– |
( |
) |
|
( |
) | ||||||||
Issuance of shares in public equity offering |
|
– |
– |
– |
– |
| ||||||||||
Share issuance costs in a public equity offering |
( |
) |
– |
– |
– |
– |
( |
) | ||||||||
Issuance of shares and warrants in a private placement |
|
– |
|
– |
– |
| ||||||||||
Share and warrant issuance costs in private placement |
( |
) |
– |
– |
– |
– |
( |
) | ||||||||
Redemption of DSU’s |
|
( |
) |
– |
– |
– |
( |
) | ||||||||
Warrants exercised |
|
– |
( |
) |
– |
– |
| |||||||||
Warrants expired |
– |
|
( |
) |
– |
– |
– | |||||||||
DSUs: | ||||||||||||||||
Value of services recognized |
– |
|
– |
– |
– |
| ||||||||||
Employee share options: | ||||||||||||||||
Value of services recognized |
– |
|
– |
– |
– |
| ||||||||||
Exercise of options |
|
( |
) |
– |
– |
– |
| |||||||||
| ||||||||||||||||
Balance, December 31, 2020 (recast – note 2) |
|
|
|
( |
) |
|
| |||||||||
| ||||||||||||||||
Balance, December 31, 2020 (recast – note 2) |
|
|
|
( |
) |
|
| |||||||||
| ||||||||||||||||
Net loss and comprehensive loss for the period |
– |
– |
– |
( |
) |
– |
( |
) | ||||||||
Issuance of shares and warrants in public equity offerings |
|
– |
|
– |
– |
| ||||||||||
Share and warrant issuance costs in public equity offerings |
( |
) |
– |
( |
) |
– |
– |
( |
) | |||||||
Redemption of DSU’s |
|
( |
) |
– |
– |
– |
( |
) | ||||||||
DSUs: | ||||||||||||||||
Value of services recognized |
– |
|
– |
– |
– |
| ||||||||||
Employee share options: | ||||||||||||||||
Value of services recognized |
– |
|
– |
– |
– |
| ||||||||||
Exercise of options |
|
( |
) |
– |
– |
– |
| |||||||||
| ||||||||||||||||
Balance, December 31, 2021 |
|
|
|
( |
) |
|
| |||||||||
The accompanying notes form an integral part of these audited annual consolidated financial statements.
| |
IMV Inc. | |
Consolidated Statements of Loss and Comprehensive Loss | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
December 31, |
December 31, | |||||
2021 |
2020 | |||||
$ |
$ | |||||
|
(recast – note 2) | |||||
Income | ||||||
Subcontract revenue |
|
| ||||
Interest income |
|
| ||||
| ||||||
|
| |||||
| ||||||
Expenses | ||||||
Research and development |
|
| ||||
General and administrative |
|
| ||||
Government assistance (note 5) |
( |
) |
( |
) | ||
Accreted interest and valuation adjustments (note 10) |
|
| ||||
| ||||||
|
| |||||
| ||||||
Net loss for the year |
( |
) |
( |
) | ||
| ||||||
Other comprehensive income | ||||||
Currency translation adjustment (note 2) |
|
| ||||
| ||||||
Total comprehensive loss for the year |
( |
) |
( |
) | ||
| ||||||
Basic and diluted loss per share |
( |
) |
( |
) | ||
| ||||||
Weighted-average shares outstanding |
|
| ||||
The accompanying notes form an integral part of these audited annual consolidated financial statements.
| |
IMV Inc. | |
Consolidated Statements of Cash Flows | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
December 31, |
December 31, | |||||
2021 |
2020 | |||||
$ |
$ | |||||
(recast – note 2) | ||||||
Cash provided by (used in) | ||||||
| ||||||
Operating activities | ||||||
Net loss for the year |
( |
) |
( |
) | ||
Charges to operations not involving cash | ||||||
Depreciation of property and equipment |
|
| ||||
Accreted interest and valuation adjustments |
|
| ||||
Fair value adjustment on government loan |
( |
) |
( |
) | ||
Loss on disposal of assets |
|
| ||||
Deferred share unit compensation |
|
| ||||
Stock-based compensation |
|
| ||||
| ||||||
( |
) |
( |
) | |||
| ||||||
Net change in non-cash working capital balances related to operations | ||||||
Decrease (increase) in amounts receivable |
|
( |
) | |||
Increase in prepaid expenses |
( |
) |
( |
) | ||
Decrease (increase) in investment tax credits receivable |
|
( |
) | |||
Increase in accounts payable, accrued and other liabilities |
|
| ||||
| ||||||
( |
) |
( |
) | |||
| ||||||
Financing activities | ||||||
Proceeds from issuance of share capital and warrants in private placement |
|
| ||||
Share and warrant issuance costs in private placement |
|
( |
) | |||
Proceeds from public equity offerings |
|
| ||||
Share Issuance costs in public equity offerings |
( |
) |
( |
) | ||
Proceeds from the exercise of stock options |
|
| ||||
Proceeds from the exercise of warrants |
|
| ||||
Proceeds from short-term borrowings |
|
| ||||
Repayment of short-term borrowings |
|
( |
) | |||
Proceeds from long-term debt |
|
| ||||
Repayment of long-term debt |
( |
) |
( |
) | ||
Repayment of lease obligation |
( |
) |
( |
) | ||
| ||||||
|
| |||||
Investing activities | ||||||
Acquisition of property and equipment |
( |
) |
( |
) | ||
| ||||||
Net change in cash and cash equivalents during the year |
|
| ||||
| ||||||
Cash and cash equivalents – Beginning of year |
|
| ||||
Effect of foreign exchange on cash and cash equivalents |
|
| ||||
| ||||||
Cash and cash equivalents – End of year |
|
| ||||
| ||||||
Supplementary cash flow | ||||||
| ||||||
Interest received |
|
|
The accompanying notes form an integral part of these annual audited consolidated financial statements.
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
1Nature of operations and going concern
IMV Inc. (the “Corporation” or “IMV”) is, through its 100% owned subsidiaries, a clinical-stage immuno-oncology company developing a portfolio of therapies based on DPX®, our novel immune-educating technology platform, that informs a specific, robust, and persistent anti-tumor immune response, offering long-lasting benefit to patients with solid or hematological cancers. Our DPX® technology is a unique and patented delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. We believe our versatile, immune-educating technology can be developed for application in a variety of therapeutic areas where generation of a target-specific immune response is expected to mitigate disease. The Corporation’s lead candidate, maveropepimut-S (or “MVP-S”, previously known as “DPX-Survivac”) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Survivin is overexpressed in most solid and liquid tumors and survivin expression is highly correlated with aggressive tumors and poor prognosis in multiple cancers. MVP-S is currently being evaluated in multiple clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma as well as ovarian, bladder and breast cancers.
The Corporation has one reportable and geographic segment. Incorporated under the Canada Business Corporations Act and domiciled in Dartmouth, Nova Scotia, Canada the shares of the Corporation are listed on the Nasdaq Stock Market and the Toronto Stock Exchange under the symbol “IMV”. The Corporation’s principal place of business is 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia, Canada and it also has corporate offices in Cambridge, MA and Quebec, QC.
These financial statements have been prepared using International Financial Reporting Standards applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. Since the Corporation’s inception, the Corporation’s operations have been financed through the sale of shares, issuance of debt, revenue from subcontracts, interest income on funds available for investment, government assistance and income tax credits. The Corporation has incurred significant operating losses (2021 -$
The ability of the Corporation to continue as a going concern is dependent upon raising additional financing through equity and non-dilutive funding and partnerships. Further, the Corporation’s loan agreement with Horizon contains certain conditions and restrictive covenants, including cross-default provision which puts IMV in default if IMV defaults on its other long-term debt obligations. The Corporation is in compliance with its debt covenants. There can be no assurance that the Corporation will have sufficient capital to fund its ongoing operations, develop or commercialize any products without future financings. These material uncertainties cast substantial doubt as to the Corporation’s ability to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The Corporation is currently pursuing financing alternatives that may include equity, debt, and non-dilutive financing alternatives including co-development through potential collaborations, strategic partnerships or other transactions with third parties, and merger and acquisition opportunities. There can be no assurance that additional financing will be available on acceptable terms or at all. If the Corporation is unable to obtain additional financing when required, the Corporation may have to substantially reduce or eliminate planned expenditures or the Corporation may be unable to continue operations.
The Corporation's ability to continue as a going concern is dependent upon its ability to fund its research and development programs and defend its patent rights. These consolidated financial statements do not reflect the
(1)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
1Nature of operations and going concern (continued)
adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if the Corporation were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.
An outbreak of a novel strain of coronavirus, identified as “COVID-19”, was declared a global pandemic by the World Health Organization on March 11, 2020. The extent to which the ongoing pandemic may cause significant disruptions to IMV’s business and greater impacts to results of operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration and severity of outbreaks, including potential future waves or cycles, the variants and the effectiveness of actions to contain and treat COVID-19. The Corporation cannot predict the duration, scope and severity of any potential business shutdowns or disruptions, including to ongoing and planned clinical studies and regulatory approval prospects. Further prolonged shutdowns or other business interruptions could result in material and negative effects to the Corporation’s ability to conduct its business in the manner and on the timelines currently planned, which could have a material adverse impact on IMV’s business, results of operations, and financial condition. The COVID-19 pandemic continues to evolve, and the Corporation will continue to monitor the effects of COVID-19 on its business.
2Basis of presentation
The Corporation prepares consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Chartered Professional Accountants of Canada Handbook – Accounting Part I, which incorporates International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).
These consolidated financial statements were approved by the Board of Directors on March 16, 2022.
Functional and presentation currency
Effective January 1, 2021, the Corporation has adopted the United States dollar ("USD") as its functional and presentation currency. Prior to this date, the functional and presentation currency was the Canadian dollar ("CAD"). The change in the functional currency from the CAD to the USD was made to more closely reflect the primary economic environment in which the Corporation currently operates. As a result of the advancement of the Corporations’s development programs, the Corporation has incurred and anticipates incurring the majority of future operating costs including research and development costs denominated mainly in USD. In addition, these costs will be financed from USD proceeds received from At-the-Market distribution agreements (“ATM”) executed in 2020. The Corporation also anticipates that potential future sales revenues and financings will be primarily denominated in USD. As such, these consolidated financial statements are measured in USD. On January 1, 2021, the change in functional currency resulted in the assets and liabilities as of December 31, 2020 being translated in USD using the exchange rate in effect on that date, and equity transactions were translated at historical rates. The change in functional currency was applied prospectively.
The change in presentation currency was applied retrospectively in accordance with IAS 8 – Accounting Policies, changes in Accounting Estimates and Errors, and therefore, these consolidated financial statements are presented in USD, together with the comparative information as at December 31, 2020, for the year ended
(2)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
2Basis of presentation (continued)
December 31, 2021, and for the consolidated statement of financial position as at January 1, 2020. For comparative purposes, historical consolidated financial statements were recast in USD by translating assets and liabilities at the closing rate in effect at the end of the respective period, revenues, expenses and cash flows at the average rate in effect for the respective period and equity transactions at historical rates. Any exchange difference resulting from the translation was included in accumulated other comprehensive income presented in shareholders’ equity.
3New standards and interpretations not yet adopted
In January 2020, the IASB issued amendments to Presentation of financial statements (“IAS 1”) to provide a more general approach to the classification of liabilities under IAS 1 based on the contractual arrangements in place at the reporting date. The amendments to IAS 1 are effective for annual reporting periods beginning on or after January 1, 2023. The Corporation is currently evaluating the impact of this amendment on its consolidated financial statements.
The IASB issued amendments to IAS 12, “Income Taxes”, on 7 May 2021. The amendments require companies to recognize deferred tax on transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. The Coproration has assessed the impact of amendments to IAS 12 and there will be no impact on the consolidated financial statements of the Corporation as a result of the adoption of this standard.
There are no other standards, interpretations or amendments to existing standards that are not yet effective that are expected to have a material impact on the consolidated financial statements of the Corporation.
4Significant accounting policies, judgements and estimation uncertainty
Basis of measurement
The consolidated financial statements have been prepared under the historical cost convention.
Consolidation
The financial statements of the Corporation consolidate the accounts of IMV Inc. and its subsidiaries. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation. There are no non-controlling interests, therefore, all loss and comprehensive loss is attributable to the shareholders of the Corporation.
Foreign currency translation
i)Functional and presentation currency
Items included in the consolidated financial statements of the Corporation are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The consolidated financial statements are presented in United States dollars, which is the Corporation’s functional currency.
(3)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
ii)Transactions and balances
Foreign currency translation of monetary assets and liabilities, denominated in currencies other than the Corporation’s functional currency, are converted at the rate of exchange in effect at the consolidated statements of financial position date. Revenue and expense items are translated at the rate of exchange in effect at the transaction date. Translation gains or losses are included in determining income or loss for the year.
Cash and cash equivalents
Cash and cash equivalents include cash on hand, balances with banks, and highly liquid temporary investments that are readily convertible to known amounts of cash.
Financial instruments
Financial assets and liabilities are recognized when the Corporation becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Corporation has transferred substantially all risks and rewards of ownership.
Financial assets and liabilities are offset and the net amount is reported in the consolidated statements of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.
Classification as debt or equity
Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.
Equity instruments
An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Corporation are recognised at the proceeds received, net of direct issue costs.
Compound instruments
The component parts of loan notes issued by the Corporation are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished.
Transaction costs that relate to the issue of the loan notes are allocated to the liability and compound instruments in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognised directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortised over the lives of the convertible loan notes using the effective interest method.
Classification and subsequent measurement
Financial instruments are classified into the following specified categories: amortized cost, fair value through other comprehensive income (“FVOCI”) or fair value through profit or loss (“FVTPL”). The classification depends
(4)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Financial Instruments (continued)
on the nature and purpose of the financial instrument and is determined at the time of initial recognition. Financial instruments do not include amounts due to or from government entities.
Derivatives embedded in contracts where the host is a financial liability are separated from the host debt contract and accounted for separately unless an election is made to account for the whole debt instrument at FVTPL or if they are not closely related to the host contract.
The Corporation has implemented the following classifications:
•
Cash and cash equivalents and amounts receivable are classified as amortized cost. After their initial fair value measurement, they are measured at amortized cost using the effective interest method; and
•
Accounts payable, accrued and other liabilities, amounts due to directors and long-term debt are classified as other amortized cost. After their initial fair value measurement, they are measured at amortized cost using the effective interest method.
•
Warrant liabilities are classified as FVTPL and are remeasured each reporting period.
Impairment of financial assets
The Corporation applies the simplified method of the expected credit loss model required under IFRS 9, Financial Instruments. Under this method, the Corporation estimates a lifetime expected loss allowance for all receivables. Receivables are written off when there is no reasonable expectation of recovery.
If there is objective evidence that an impairment loss has incurred, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows. The present value of the estimated future cash flows is discounted at the financial asset’s original effective interest rate.
Property and equipment
Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Corporation and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statements of loss and comprehensive loss during the period in which they are incurred.
Depreciation of property and equipment is calculated using the declining-balance method, with the exception of leasehold improvements, right-of-use assets and leased premises, at the following annual rates:
Computer equipment |
|
% |
|
Computer software |
|
% |
|
Furniture and fixtures |
|
% |
|
Laboratory equipment |
|
% |
|
Leasehold improvements, leased premises, and right-of-use assets |
|
|
(5)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Property and Equipment (continued)
Residual values, method of depreciation and useful lives of the assets are reviewed annually and adjusted if appropriate.
Gains and losses on disposals of property and equipment are determined by comparing the proceeds with the carrying amount of the asset and are included as part of general and administrative expenses in the consolidated statements of loss and comprehensive loss.
Property and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or “CGU”s). The recoverable amount is the higher of an asset’s fair value less the costs to sell, and value in use (being the present value of the expected future cash flows of the relevant asset or CGU).
An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount.
The Corporation evaluates impairment losses for potential reversals when events or circumstances warrant such consideration.
Leases
Under IFRS 16, Leases, the Corporation assesses whether a contract is or contains a lease based on the definition of a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Corporation assesses whether:
•
the contract involves the use of an identified asset, specified either explicitly or implicitly, that is physically distinct, and usage represents substantially all of the capacity of the asset;
•
the Corporation has the right to obtain substantially all of the economic benefits from use of the asset; and
•
the Corporation has the right to direct use of the asset, which is evidenced by decision-making rights to direct how and for what purpose the asset is used.
The Corporation recognizes an asset and a lease liability at the lease commencement date. The asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred, less any incentives received. The asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the asset or the end of the lease term. The estimated useful lives of leased assets are determined on the same basis as those of property and equipment. The carrying amount of the leased asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability, if any.
(6)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Leases (continued)
The lease liability is initially measured at the present value of future lease payments, discounted using the interest rate implicit in the lease, or, if that rate cannot be readily determined, the Corporation’s incremental borrowing rate. Generally, the Corporation uses its incremental borrowing rate as the discount rate. The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured if the Corporation changes its assessment of whether it will exercise a purchase, extension, or termination option. If the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the leased asset, or is recorded in the consolidated statements of loss and comprehensive loss if the carrying value of the leased asset is zero.
The Corporation has elected not to recognize assets and lease liabilities for short-term leases with a term of 12 months or less, and leases of low value assets.
The lease payments associated with these leases are recognized as an expense in the consolidated statements of loss and comprehensive loss over the lease term. Low value assets consist primarily of computers and information technology equipment.
Income tax
Income tax is comprised of current and deferred income tax. Income tax is recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.
Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.
In general, deferred income tax is recognized in respect of temporary differences including non-refundable investment tax credits, arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements.
Deferred income tax is determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the deferred income tax asset or liability is settled. Deferred income tax assets are recognized to the extent that it is probable that the assets can be recovered.
Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except in the case of subsidiaries, where the timing of the reversal of the temporary difference is controlled by the Corporation and it is probable that the temporary difference will not reverse in the foreseeable future.
Deferred income tax assets and liabilities are presented as non-current.
(7)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Research and development
All research costs are expensed in the period incurred. Development costs are expensed in the period incurred, unless they meet the criteria for capitalization, in which case, they are capitalized and then amortized over the useful life. Development costs are written off when there is no longer an expectation of future benefits.
Revenue recognition
Revenue is recognized as the Corporation satisfies its performance obligations under the terms of the contract. Performance obligations are considered to be satisfied when the customer obtains control of the related asset. Current and expected future revenue streams include: (i) milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones; (ii) future royalties generated from the eventual commercialization of the Corporation’s products; and (iii) amounts generated for providing formulation and research support services related to existing licensing and research agreements with partners.
Revenue resulting from formulation services is recognized in the accounting period in which the formulation is delivered to the customer. Typically, the customer does not have control of the asset while services are being performed and, therefore, revenues are recognized at the time the Corporation has completed its obligation and the customer obtains control of the asset.
Revenue resulting from research support services is recognized over time as the services are performed, as the customer benefits simultaneously from the service, and as the Corporation satisfies its performance obligation.
The Corporation expects to generate upfront payments, milestone and royalty revenues from future licenses for the Corporation’s products. Upfront payments and milestones will be recognized as revenue when or as the underlying obligations are achieved and are not conditional on any further performance, which could be at a point in time or over time depending on the contractual terms. Royalty revenue will be recognized in the period in which the Corporation earns the royalty.
The Corporation does not generate licensing or royalty revenues at this time.
Share capital
Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from share capital.
Loss per share
Basic loss per share (“LPS”) is calculated by dividing the net loss for the year attributable to equity owners of the Corporation by the weighted average number of common shares outstanding during the year.
Diluted LPS is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is
(8)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Loss per share (continued)
computed using the treasury stock method. Diluted LPS is equal to the LPS as the Corporation is in a loss position and all securities, comprised of options and warrants, would be anti-dilutive.
Stock-based compensation plan
The Corporation grants stock options to certain employees and non-employees. Beginning January 1, 2018,
A holder of an option may, rather than exercise such option, elect a cashless exercise of such option payable in common shares equaling the amount by which the value of an underlying share at that time exceeds the exercise price of such option or warrant to acquire such share.
Deferred share unit plan (“DSU” Plan)
The Corporation grants deferred share units (“DSUs”) to members of its Board of Directors (“Board Members”), who are not employees or officers of the Corporation. DSUs cannot be redeemed until the holder is no longer a director of the Corporation and are considered equity-settled instruments. In accordance with the DSU Plan, DSUs for ongoing services are granted quarterly and vest immediately. The Board Members can also grant DSUs at its discretion, which may vest over time. The value attributable to DSUs is based on the market value at the time of grant and a compensation expense is recognized in general and administrative expenses on the consolidated statements of loss and comprehensive loss in accordance with the vesting terms. At the time of redemption, each DSU may be exchanged for one common share of IMV Inc., net of applicable withholding taxes.
Government assistance
Government assistance consists of non-repayable government grants, from a number of government agencies and the difference between the fair value and the book value of repayable low-interest government loans, recorded initially at fair value. Government assistance is recorded in the period earned using the cost reduction method and is included in government assistance on the consolidated statements of loss and comprehensive loss.
Research and development tax credits
Refundable investment tax credits relating to scientific research and experimental development expenditures (“SR&ED”) are recorded in the accounts in the fiscal period in which the qualifying expenditures are incurred provided there is reasonable assurance that the tax credits will be realized. Refundable investment tax credits, in connection with SR&ED activities, are accounted for using the cost reduction method and included in government assistance on the statements of loss and comprehensive loss.
(9)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Research and development tax credits (continued)
Amounts recorded for refundable investment tax credits are calculated based on the expected eligibility and tax treatment of qualifying SR&ED expenditures recorded in the Corporation’s consolidated financial statements.
Critical accounting estimates and judgments
The Corporation makes estimates and assumptions concerning the future that will, by definition, seldom equal actual results. The following are the estimates and judgments applied by management that most significantly affect the Corporation’s consolidated financial statements.
The following estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.
Calculation of initial fair value and carrying amount of long-term debt
Atlantic Canada Opportunities Agency (“AOCA”) conditionally repayable loans (“Conditional ACOA”) loans
The initial fair value of the Conditional ACOA loans is determined by using a discounted cash flow analysis for each of the loans, which require a number of assumptions. The difference between the face value and the initial fair value of the Conditional ACOA loans is recorded in the consolidated statements of loss and comprehensive loss as government assistance. The carrying amount of the Conditional ACOA loans requires management to adjust the long-term debt to reflect actual and revised estimated cash flows whenever revised cash flow estimates are made or new information related to market conditions is made available. Management recalculates the carrying amount by computing the present value of the estimated future cash flows at the original effective interest rate. Any adjustments are recognized in the consolidated statements of loss and comprehensive loss as accreted interest and other adjustments after initial recognition.
The significant assumptions used in determining the discounted cash flows include estimating the amount and timing of future revenue for the Corporation and the discount rate.
As the Conditional ACOA loans are repayable based on a percentage of gross revenue, if any, the determination of the amount and timing of future revenue significantly impacts the initial fair value of the loan, as well as the carrying value of the Conditional ACOA loans at each reporting date. The expected revenue streams include i) estimated royalties generated from the eventual commercialization of the Corporation’s products, and ii) estimated milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones. The amount and timing of estimated milestone payments forecasted are earlier and less predictable, therefore, changes in the amount and timing of milestone payments could have a significant impact on the fair value of the loans. Further, the Corporation is in the early stages of research for its product candidates; accordingly, determination of the amount and timing of any revenue streams requires significant judgment by management.
The discount rate determined on initial recognition of the Conditional ACOA loans is used to determine the present value of estimated future cash flows expected to be required to settle the debt. In determining the appropriate discount rates, the Corporation considered the interest rates of similar long-term debt arrangements
(10)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
4Significant accounting policies, judgements and estimation uncertainty (continued)
Critical accounting estimates and judgments (continued)
with similar terms. The Conditional ACOA loans are repayable based on a percentage of gross revenue, if any; accordingly, finding financing arrangements with similar terms is difficult and management was required to use significant judgment in determining the appropriate discount rates. Management used a discount rate of
If the weighted average discount rate used in determining the initial fair value and the carrying value at each reporting date of all Conditional ACOA loans, with repayment terms based on future revenue, had been determined to be
5Government grants and assistance
The Corporation is evaluating all applicable government relief programs. Notably, in response to the negative economic impact of COVID-19, the Government of Canada, in collaboration with the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”), announced the Innovation Assistance Program (“IAP”) program in April 2020. IAP provides a wage subsidy on eligible remuneration, subject to limits per employee, to eligible employers pursuing technology driven innovation who are not eligible for funding under the Canada Emergency Wage Subsidy. In 2020, the Corporation qualified for this subsidy from the April 1, 2020 effective date through to June 23, 2020, and has, accordingly, recognized $
In July 2020, the Corporation qualified for $
In August 2020, the Corporation qualified for COVID-19 project funding from the Atlantic Canada Opportunities Agency (“ACOA”). ACOA’s contribution is an interest free government loan with a maximum contribution of $
In May 2020, the Corporation qualified for $
(11)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
5Government grants and assistance (continued)
salaries and
In October 2020, the Corporation qualified for an additional $
6Amounts Receivable
December 31, |
December 31, |
January 1, | ||||||
2021 |
2020 |
2020 | ||||||
$ |
$ |
$ | ||||||
(recast – note 2) |
(recast – note 2) | |||||||
| ||||||||
Amounts due from government assistance and government loans |
|
|
| |||||
Sales tax receivable |
|
|
| |||||
Revenue from subcontracts |
|
|
| |||||
Other |
|
|
| |||||
|
|
| ||||||
|
7Accounts payable, accrued and other liabilities
December 31, |
December 31, |
January 1, | ||||||
2021 |
2020 |
2020 | ||||||
$ |
$ |
$ | ||||||
(recast – note 2) |
(recast – note 2) | |||||||
| ||||||||
Trade payables |
|
|
| |||||
Accrued and other liabilities |
|
|
| |||||
Payroll taxes |
|
|
| |||||
Amounts due to Directors |
|
|
| |||||
|
|
| ||||||
|
(12)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
8Leases
Amount | |||
$ | |||
| |||
Balance – January 1, 2020 (recast – note 2) |
| ||
| |||
Additions |
| ||
| |||
Repayment of lease obligation |
( |
) | |
| |||
Accreted interest |
| ||
| |||
Currency translation adjustment |
| ||
| |||
Balance – December 31, 2020 (recast – note 2) |
| ||
| |||
Additions and valuation adjustments |
| ||
| |||
Repayment of lease obligation |
( |
) | |
| |||
Accreted interest |
| ||
| |||
Currency translation adjustment |
| ||
| |||
Balance – December 31, 2021 |
| ||
| |||
Less: Current portion |
( |
) | |
| |||
Non-current portion |
| ||
The Corporation recognizes a right-of-use asset and lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the liability, discounted at an incremental borrowing rate of
On July 26, 2021 the Corporation signed a lease for
(13)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
9Property, plant and equipment
Computer | ||||||||||||||||||
equipment | ||||||||||||||||||
and |
Furniture |
Laboratory |
Right-of- |
Leasehold | ||||||||||||||
software |
and fixtures |
equipment |
use assets |
improvements |
Total | |||||||||||||
$ |
$ |
$ |
$ |
$ |
$ | |||||||||||||
| ||||||||||||||||||
Year ended December 31, 2020 | ||||||||||||||||||
Opening net book value (recast) |
|
|
|
|
|
| ||||||||||||
Additions |
|
|
|
|
|
| ||||||||||||
Disposals | ||||||||||||||||||
Cost |
( |
) |
|
( |
) |
|
|
( |
) | |||||||||
Accumulated depreciation |
|
|
|
|
|
| ||||||||||||
Depreciation for the year |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||
Impact of foreign exchange rate changes |
|
|
|
|
|
| ||||||||||||
| ||||||||||||||||||
Closing net book value |
|
|
|
|
|
| ||||||||||||
| ||||||||||||||||||
As at December 31, 2020 (recast) | ||||||||||||||||||
Cost |
|
|
|
|
|
| ||||||||||||
Accumulated depreciation |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||
Impact of foreign exchange rate changes |
( |
) |
|
( |
) |
|
|
| ||||||||||
| ||||||||||||||||||
Net book value |
|
|
|
|
|
| ||||||||||||
| ||||||||||||||||||
Year ended December 31, 2021 | ||||||||||||||||||
Opening net book value |
|
|
|
|
|
| ||||||||||||
Additions |
|
|
|
|
|
| ||||||||||||
Disposals | ||||||||||||||||||
Cost |
|
|
( |
) |
|
|
( |
) | ||||||||||
Accumulated depreciation |
|
|
|
|
|
| ||||||||||||
Depreciation for the year |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||
Impact of foreign exchange rate changes |
( |
) |
|
( |
) |
( |
) |
( |
) |
( |
) | |||||||
| ||||||||||||||||||
Closing net book value |
|
|
|
|
|
| ||||||||||||
| ||||||||||||||||||
As at December 31, 2021 | ||||||||||||||||||
Cost |
|
|
|
|
|
| ||||||||||||
Accumulated depreciation |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||
Impact of foreign exchange rate changes |
|
|
|
|
|
| ||||||||||||
| ||||||||||||||||||
Net book value |
|
|
|
|
|
| ||||||||||||
(14)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
10Long-term debt
December 31, 2021 |
December 31, 2020 |
January 1, 2020 | ||||||||
$ |
$ |
$ | ||||||||
(recast – note 2) |
(recast – note 2) | |||||||||
ACOA Atlantic Innovation Fund (“AIF”), interest-free loan1 with a maximum contribution of CAD$ |
|
|
| |||||||
| ||||||||||
ACOA AIF, interest-free loan1 with a maximum contribution of CAD$ |
|
|
| |||||||
| ||||||||||
ACOA Business Development Program, interest-free loan with a maximum contribution of CAD$ |
|
|
| |||||||
| ||||||||||
ACOA AIF, interest-free loan1 with a maximum contribution of CAD$ |
|
|
| |||||||
| ||||||||||
TNC 120-140 Eileen Stubbs Ltd. (the Landlord) loan, with an original balance of CAD$ |
|
|
|
(15)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
10Long-term debt (continued)
| ||||||||||
Province of Nova Scotia (the “Province”), secured loan with a maximum contribution of CAD$ |
|
|
| |||||||
| ||||||||||
ACOA Regional Economic Growth through Innovation1 – Business Scale-Up and Productivity Program, interest-free loan with a maximum contribution of CAD$ |
|
|
| |||||||
Venture loan with Horizon Technology Finance Corporation and Powerscourt investments XXV, LP (“Venture Loan”) bearing interest at The Wall Street Journal prime rate plus 5.75%, compounded annually and payable monthly, maturity on July 1, 2025, with effective interest rate of |
|
|
| |||||||
|
|
| ||||||||
Less: current portion |
|
|
| |||||||
|
|
| ||||||||
1These loans are repayable based on a percentage of gross revenue, if any. The carrying amount of these loans is reviewed each reporting period and adjusted as required to reflect management’s best estimate of future cash flows, based on a number of assumptions, discounted at the original effective interest rate. |
Total contributions received, less amounts that have been repaid as at December 31, 2021, is $
(16)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
10Long-term debt (continued)
Venture Loan with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP
On December 17, 2021, the Corporation was issued a $
Monthly pro rata principal repayments start after 24 months from loan inception. If a predetermined milestone is reached, the start date for the repayment of principal is deferred for 6 months, with no extension of maturity.
The Corporation may, at its option, at any time, prepay all the outstanding Venture Loan by simultaneously paying to the lenders an amount equal to any accrued and unpaid interest, the outstanding principal balance and the final payments of the Venture Loan plus an amount equal to:
a)3% in the 18 first months of the loan;
b)2% in the months 19 to 30 of the loan;
c)1% in the last 12 months of the loan (31 to 42).
The prepayment option is an embedded derivative, but has insignificant value on issuance date.
The Venture Loan has a priority security interest in all assets of IMV, excluding intellectual property. IMV has entered into a negative pledge agreement regarding intellectual property with the lenders.
Province of Nova Scotia Loan
In September 2021, the Corporation amended its loan agreement with the Province. Prior to the amendment, the maturity date of the loan was December 1, 2025. Following the amendment, The Corporation was not required to resume repaying the balance of the principal amount until the first day of July 2023, by making the remaining 54 monthly principal payments of CAD$
(17)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
10Long-term debt (continued)
The minimum annual principal repayments of long-term debt over the next five years, excluding the repayments of the Conditional ACOA loans for 2021 and beyond which are not determinable at this time, are as follows:
$ | |||
Year ending December 31, 2022 |
| ||
2023 |
| ||
2024 |
| ||
2025 |
| ||
2026 |
|
December 31, 2021 |
December 31, 2020 | |||||||
$ |
$ | |||||||
(recast – note 2) | ||||||||
Balance – Beginning of period |
|
| ||||||
Borrowings |
|
| ||||||
Accreted interest and valuation adjustments |
|
| ||||||
Revaluation of long-term debt |
( |
) |
( |
) | ||||
Repayment of debt |
( |
) |
( |
) | ||||
Currency translation adjustment (note 2) |
|
| ||||||
Balance – End of period |
|
| ||||||
Less: Current portion |
|
| ||||||
Non-current portion |
|
| ||||||
| ||||||||
11Warrant liabilites
In conjunction with the Venture Loan with Horizon Technology Finance Corporation and Powerscourt Investments XXV, six warrants have been issued to the lenders. Combined, these warrants allow the holder to purchase
The fair values of warrants are estimated using the Black-Scholes option pricing model. The weighted average assumptions used in the Black-Scholes valuation model for the periods presented were as follows:
December 31, 2021 |
December 17, 2020 | |||||
$ |
$ | |||||
Risk-free interest rate |
|
| ||||
Market price |
$ |
$ | ||||
Expected volatility |
|
| ||||
Expected dividend yield |
|
| ||||
Expected life (years) |
|
| ||||
(18)
| |
IMV Inc. | |
Notes to the Consolidated Financial Statements | |
For the years ended December 31, 2021 and 2020 | |
(Expressed in thousands of United States dollars except for share and per share amounts) |
12Share capital
Authorized
Unlimited number of common shares and preferred shares, issuable in series, all without par value.
Common shares |
Amount | ||||
# |
$ | ||||
Issued and outstanding | |||||
Balance – January 1, 2020 (recast – note 2) |
|
| |||
Issued for cash, net of issuance costs |
|
| |||
Stock options exercised |
|
| |||
DSUs redeemed |
|
| |||
Warrants exercised |
|
| |||
Balance – December 31, 2020 (recast – note 2) |
|
| |||
Issued for cash, net of issuance costs |
|
| |||
DSUs redeemed |
|
| |||
Stock options exercised |
|
| |||
Balance – December 31, 2021 |
|
| |||
As at December 31, 2021, a total of
On July 20, 2021, the Corporation completed the July 2021 Public Offering, issuing an aggregate of